• LAST PRICE
    14.3900
  • TODAY'S CHANGE (%)
    Trending Up0.9400 (6.9888%)
  • Bid / Lots
    14.0100/ 1
  • Ask / Lots
    14.3900/ 2
  • Open / Previous Close
    13.2500 / 13.4500
  • Day Range
    Low 13.2500
    High 14.7200
  • 52 Week Range
    Low 8.4450
    High 37.0000
  • Volume
    351,762
    above average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Wednesday's close: 13.45
TimeVolumeEFTR
09:32 ET250613.4814
09:34 ET125713.55
09:36 ET825513.7618
09:38 ET319913.9
09:39 ET809913.81
09:41 ET188613.705
09:43 ET30013.705
09:45 ET90013.9
09:48 ET150913.71
09:50 ET140013.75
09:52 ET609514.04
09:54 ET636714.09
09:56 ET28014
09:57 ET20014.02
09:59 ET127313.974
10:01 ET420013.9101
10:03 ET232014.065
10:06 ET673314.1459
10:08 ET50014
10:10 ET76814.2
10:12 ET453314.2001
10:14 ET612814.0514
10:15 ET313313.6525
10:17 ET116913.871
10:19 ET10013.87
10:21 ET200013.861
10:24 ET618413.86
10:26 ET284313.7499
10:28 ET61213.7499
10:30 ET10013.74
10:33 ET118213.65
10:37 ET50413.75
10:44 ET10013.96
10:46 ET529713.8999
10:50 ET16013.87
10:51 ET20013.9679
10:53 ET318014
10:55 ET10014.1
10:57 ET120014.08
11:00 ET20014.14
11:04 ET85413.98
11:09 ET10813.8783
11:11 ET60013.93
11:13 ET97413.98
11:15 ET50013.97
11:22 ET30013.75
11:26 ET196013.7
11:31 ET52013.98
11:33 ET189013.7623
11:40 ET20013.98
11:45 ET131413.6247
11:49 ET30013.91
11:54 ET30013.7448
11:58 ET20013.7914
12:02 ET220013.8899
12:03 ET56313.77
12:12 ET20013.71
12:14 ET150013.86
12:16 ET923013.8474
12:18 ET360013.9004
12:20 ET931014.31
12:21 ET100014.3899
12:23 ET132514.25
12:27 ET372914.27
12:34 ET359214.345
12:36 ET900014.355
12:38 ET50014.2301
12:41 ET30014.3
12:43 ET90014.2794
12:45 ET100014.45
12:48 ET515714.48
12:50 ET885214.4457
12:52 ET1392914.65
12:54 ET612514.68
12:56 ET50014.66
12:57 ET230114.605
12:59 ET916714.13
01:01 ET1835713.88
01:03 ET99814.4444
01:06 ET99214.0467
01:08 ET43914.1
01:10 ET80613.5501
01:21 ET15513.98
01:24 ET85014.26
01:26 ET50014.115
01:32 ET64214.37
01:33 ET46914.37
01:39 ET180814.1167
01:42 ET622414.33
01:44 ET10014.225
01:50 ET540014.33
01:51 ET1460114.385
01:53 ET12014.5
01:55 ET47314.6396
01:57 ET59714.5
02:02 ET200014.3071
02:04 ET42414.2742
02:06 ET30014.465
02:08 ET16014.56
02:09 ET60014.22
02:29 ET199214.58
02:31 ET29814.6
02:33 ET10014.58
02:38 ET20014.41
02:44 ET48314.27
02:49 ET44414.52
02:58 ET60014.5
03:05 ET24914.55
03:07 ET220514.4712
03:09 ET10014.48
03:12 ET70014.45
03:14 ET34614.4456
03:16 ET300014.4432
03:18 ET1067014
03:20 ET10014
03:21 ET999714.3996
03:27 ET50014.1701
03:32 ET98014.31
03:36 ET170014.43
03:38 ET1161714.4
03:39 ET80914.35
03:45 ET117214.3
03:48 ET20014.11
03:50 ET289614.35
03:56 ET30414.4754
03:57 ET10014.34
03:59 ET230014.39
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesEFTR
eFFECTOR Therapeutics Inc
53.1M
-0.7x
---
United StatesMTNB
Matinas BioPharma Holdings Inc
58.9M
-2.8x
---
United StatesDYAI
Dyadic International Inc
48.1M
-7.0x
---
United StatesMRKR
Marker Therapeutics Inc
38.3M
-2.7x
---
United StatesSLS
Sellas Life Sciences Group Inc
55.7M
-0.7x
---
United StatesELTX
Elicio Therapeutics Inc
63.9M
-0.8x
---
As of 2024-03-29

Company Information

eFFECTOR Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of oncology drugs, such as selective translation regulator inhibitors (STRIs). The Company uses a selective translation regulation technology platform to internally discover a portfolio of small molecule STRI product candidates. Its product candidates target the eIF4F complex and its activating kinase, MNK. The Company’s lead product candidate, tomivosertib, is an inhibitor of MNK, and is being evaluated in combination with KEYTRUDA (pembrolizumab), an FDA-approved inhibitor of programmed cell death protein 1 (PD-1) in a randomized Phase 2b clinical trial in patients with metastatic non-small cell lung cancer (NSCLC). Its second product candidate, zotatifin, is an inhibitor of eIF4A, a component of the eIF4F complex, and is being evaluated in a Phase 1/2 clinical trial in patients with certain solid tumors. Its third program is focused on developing inhibitors of eIF4E.

Contact Information

Headquarters
142 North Cedros Avenue Suite B, Suite ASOLANA BEACH, CA, United States 92075
Phone
858-925-8215
Fax
302-655-5049

Executives

Independent Chairman of the Board
Brian Gallagher
President, Chief Executive Officer, Director
Stephen Worland
Chief Financial Officer
Michael Byrnes
Chief Medical Officer
Douglas Warner
Director
Caroline Loewy

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$53.1M
Revenue (TTM)
$675.0K
Shares Outstanding
3.7M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
---
EPS
$-19.26
Book Value
$2.34
P/E Ratio
-0.7x
Price/Sales (TTM)
78.6
Price/Cash Flow (TTM)
---
Operating Margin
-5,032.44%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.